Christian Nanoff

ORCID: 0000-0002-8857-2470
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Receptor Mechanisms and Signaling
  • Adenosine and Purinergic Signaling
  • Neuroscience and Neuropharmacology Research
  • Neuropeptides and Animal Physiology
  • Protein Kinase Regulation and GTPase Signaling
  • Ion channel regulation and function
  • Nitric Oxide and Endothelin Effects
  • Chemical Synthesis and Analysis
  • Pharmacological Receptor Mechanisms and Effects
  • Amino Acid Enzymes and Metabolism
  • Pancreatic function and diabetes
  • Photoreceptor and optogenetics research
  • Parkinson's Disease Mechanisms and Treatments
  • Peptidase Inhibition and Analysis
  • Circadian rhythm and melatonin
  • Monoclonal and Polyclonal Antibodies Research
  • Biochemical and Molecular Research
  • Neurotransmitter Receptor Influence on Behavior
  • Thyroid and Parathyroid Surgery
  • Heat shock proteins research
  • Cellular transport and secretion
  • Diet and metabolism studies
  • Muscle metabolism and nutrition
  • Diabetes Treatment and Management
  • Radiopharmaceutical Chemistry and Applications

Medical University of Vienna
2011-2025

University of Vienna
2000-2024

Institute of Pharmacology
2000-2005

Boehringer Ingelheim (Austria)
2005

Universität Ulm
2002

University of Chicago
1998-2001

Austrian Economics Center
2000

Institut Cochin
1999

Duke University Hospital
1991-1993

Duke Medical Center
1991-1993

Abstract Mel 1a melatonin receptors belong to the superfamily of guanine nucleotide-binding regulatory protein (G protein)-coupled receptors. So far, interest in receptor signaling has focused mainly on modulation adenylyl cyclase pathway via pertussis toxin (PTX)-sensitive G proteins. To further investigate human receptor, we have developed an antibody directed against C terminus this receptor. This detected as a with apparent molecular mass approximately 60 kDa immunoblots after separation...

10.1210/mend.13.12.0390 article EN Molecular Endocrinology 1999-12-01

Glutamatergic neurotransmission is controlled by presynaptic metabotropic glutamate receptors (mGluRs). A subdomain in the intracellular carboxyl-terminal tail of group III mGluRs binds calmodulin and heterotrimeric guanosine triphosphate–binding protein (G protein) βγ subunits a mutually exclusive manner. Mutations interfering with binding antagonists inhibit G protein–mediated modulation ionic currents mGluR 7. Calmodulin also prevent inhibition excitatory via mGluRs. These results reveal...

10.1126/science.286.5442.1180 article EN Science 1999-11-05

G protein alpha subunits expose specific binding sites that allow for the sequential, conformation-dependent of reaction partners, e.g., beta gamma dimers, receptors, and effectors. These domains represent potential low-molecular-weight inhibitors. We tested following suramin analogues as antagonists: 8-(3-nitrobenzamido)-1,3,5-naphtalenetrisulfonic acid (NF007), 8-(3-(3-nitrobenzamido)benzamido)-1,3,5-naphtalenetrisulfonic++ + NF018),...

10.1016/s0026-895x(25)08769-3 article EN Molecular Pharmacology 1996-04-01

Many membrane proteins incur a folding problem during biosynthesis; only fraction thereof is exported from the endoplasmic reticulum (ER), because quality control stringent. This also true for G protein-coupled receptors. Here, we identify deubiquitinating enzyme Usp4 as an interaction partner of A2a adenosine receptor, Gs-coupled receptor. binds to carboxyl terminus A2A receptor and allows its accumulation deubiquinated protein. relaxes ER enhances cell surface expression functionally...

10.1124/mol.105.015818 article EN Molecular Pharmacology 2005-12-09

Signaling by D<sub>2</sub>-dopamine receptors in neurons likely proceeds the presence of Ca<sup>2+</sup> oscillations. We describe here biochemical basis for a cross-talk between intracellular and D<sub>2</sub> receptor. By activation calmodulin (CaM), directly inhibits receptor; this conclusion is based on following observations: (i) The receptor contains CaM-binding motif NH<sub>2</sub>-terminal end third loop, domain involved activating G<sub>i/o</sub>. A peptide fragment encompassing...

10.1074/jbc.m002780200 article EN cc-by Journal of Biological Chemistry 2000-10-01

Suramin acts as a G protein inhibitor because it inhibits the rate-limiting step in activation of α subunit, i.e., exchange GDP for GTP. Here, we have searched analogues that are selective sα . Two compounds been identified: NF449 (4,4′,4",4′"-[carbonyl-bis[imino-5,1,3-benzenetriyl bis-(carbonylimino)]]tetrakis-(benzene-1,3-disulfonate) and NF503 (4,4′-[carbonylbis[imino-3,1-phenylene-(2,5-benzimidazolylene)carbonylimino]]bis-benzenesulfonate). These ( i ) suppress association rate guanosine...

10.1073/pnas.95.1.346 article EN Proceedings of the National Academy of Sciences 1998-01-06

Suramin analogues act as direct antagonists of heterotrimeric G proteins because they block the rate-limiting step protein activation (i.e., dissociation GDP prebound to alpha subunit). We have used human brain A1 adenosine receptor and rat striatal D2 dopamine receptor, two prototypical Gi/G(o)-coupled receptors, a model system test whether following suppress receptor-dependent proteins: 8-(3-nitrobenzamido)-1,3,5-naphthalenetrisulfonic acid (NF007),...

10.1016/s0026-895x(25)09262-4 article EN Molecular Pharmacology 1996-08-01

The purified bovine brain A,-adenosine receptor has previously been shown to discriminate among closely related G protein a-subunits.To obtain analogous information for the human receptor, cDNA coding was inserted into a plasmid placing synthesis of under control MalE promoter.Following induction by maltose, active accumulated in Escherichia coli membranes.Binding antagonist S-~3Hlcyclopentyl-l,3-dipropylxanthine E. membranes (K, -2 MI, B,, -0.2-0.4 pmoYmg) showed appropriate pharmacological...

10.1016/s0021-9258(18)31603-x article EN cc-by Journal of Biological Chemistry 1994-12-01

If stably expressed in human embryonic kidney (HEK)293 cells, the Mel<sub>1a</sub>-melatonin receptor activates G<sub>i</sub>-dependent, pertussis toxin-sensitive signaling pathways, i.e., inhibition of adenylyl cyclase and stimulation phospholipase Cβ; latter on condition that G<sub>q</sub> is coactivated. The antagonist luzindole blocks effects melatonin acts as an inverse agonist at Mel<sub>1a</sub> both intact cells isolated membranes. This suggests Mel<sub>1a</sub>receptor endowed with...

10.1124/mol.56.5.1014 article EN Molecular Pharmacology 1999-11-01

Ulcerous lesions can arise in primary skin cancers and upon infiltration of the by malignant cells originating from other organs. These fungating wounds are difficult to treat, they cause pain, itching malodor. Distressing malodor imposes a major burden on patients. The carrion odor decaying tissue is—at least part—due bacterial breakdown products cadaverine putrescine. Here, we examined binding cadaverine, histamine, putrescine, spermidine spermine preparation micronized purified...

10.3390/scipharm93010007 article EN cc-by Scientia Pharmaceutica 2025-01-23

UTP stimulates transmitter release and inhibits M-type K(+) channels in rat superior cervical ganglion neurons via G protein-coupled P2Y receptors. To investigate the underlying signaling mechanisms, we treated with either pertussis or cholera toxin; neither treatment altered inhibition of by 10 microM UTP. However, toxin reduced UTP-evoked [(3)H]noradrenaline 66%. UTP, UDP, ATP, ADP caused accumulation inositol trisphosphate a toxin-insensitive manner. Pharmacological trisphosphate-induced...

10.1016/s0026-895x(24)23226-0 article EN Molecular Pharmacology 2000-06-01

Agonist binding to the A2 adenosine receptor (A2AR) and its regulation by guanine nucleotides was studied using newly developed radioligand 125I-2-[4-(2-[2-[(4-aminophenyl)methylcarbonylamino] ethylaminnocarbonyl]ethyl)phenyl]ethylamino-5'-N- ethylcarboxamidoadenosine (125I-PAPA-APEC) photoaffinity analog 125I-azido-PAPA-APEC. A single protein of Mr 45,000, displaying appropriate A2AR pharmacology, is labeled in membranes from bovine striatum, PC12 cells, frog erythrocytes. In DDT1 MF2 cells...

10.1016/s0026-895x(25)10955-3 article EN Molecular Pharmacology 1991-02-01

Blockage of <i>β</i><sub>1</sub>-adrenergic receptors is one the most effective treatments in cardiovascular medicine. Esmolol was introduced some three decades ago as a short-acting <i>β</i><sub>1</sub>-selective antagonist. Landiolol more recent addition. Here we compared two compounds for their selectivity over <i>β</i><sub>2</sub>-adrenergic receptors, partial agonistic activity, signaling bias, and pharmacochaperoning action by using human embryonic kidney (HEK)293 cell lines, which...

10.1124/jpet.116.232884 article EN Journal of Pharmacology and Experimental Therapeutics 2016-07-22

Hypoparathyroidism is a common sequela of thyroid surgery; in this study, we aimed at exploring the pathogenesis behind it. The following premises suggest that wound fluid might be causative agent. (i) Parathyroid hormone secretion under feedback control by calcium-sensing receptor, which responds to diverse array activating ligands. (ii) Postoperative hypoparathyroidism arises from secretory deficiency parathyroid glands. Even patients later unaffected hypoparathyroidism, levels drop within...

10.1021/acsptsci.3c00350 article EN cc-by ACS Pharmacology & Translational Science 2024-06-28

Reconstitution experiments with purified components reproduce the basic characteristics of receptor/G protein coupling, i.e., GTP-sensitive high affinity agonist binding and receptor-promoted GTP binding. However, interaction agonists A1 adenosine receptor in rat bovine but not human brain membranes deviates from ternary complex model since agonist/receptor/G cannot be dissociated by concentrations (> or = 100 microM) hydrolysis-resistant analogue gamma S. The reason for this phenomenon...

10.1016/s0026-895x(25)10537-3 article EN Molecular Pharmacology 1995-11-01

The carboxyl terminus (C-tail) of G protein-coupled receptors is divergent in length and structure may represent an individualized cytoplasmic domain. By progressively truncating the A1 adenosine receptor, a Gi/o-coupled receptor with short stretches, we identify two inherent functions C-tail, namely role export from endoplasmic reticulum (ER) protein coupling. Deletion last 22 26 amino acids (of 36) reduced completely abolished surface expression respectively. severely truncated were...

10.1074/jbc.m212918200 article EN cc-by Journal of Biological Chemistry 2003-08-01

Ca<sup>2+</sup>/calmodulin (Ca<sup>2+</sup>/CaM) and the βγ subunits of heterotrimeric G-proteins (Gβγ) have recently been shown to interact in a mutually exclusive fashion with intracellular C terminus presynaptic metabotropic glutamate receptor 7 (mGluR 7). Here, we further characterized core CaM Gβγ binding sequences. In contrast previous report, find that motif localized N-terminal region cytoplasmic tail domain mGluR is conserved related group III mGluRs 4A 8 allows these receptors also...

10.1074/jbc.m102573200 article EN cc-by Journal of Biological Chemistry 2001-08-01

(–)Isoprenaline was continuously administered to rats at a rate of 0.4 mg/kg/h for 7 days via subcutaneously (s.c.) implanted osmotic minipumps. This treatment induced cardiac hypertrophy and marked decrease in basal as well catecholamine-stimulated adenylate cyclase activity ventricular plasma membrane fraction. The total number (β-adrenoceptors downregulated by one-half the amount receptor sites obtained control group. However, isoprenaline-treated group, constituted significantly smaller...

10.1097/00005344-198902000-00004 article EN Journal of Cardiovascular Pharmacology 1989-02-01

Exchanging each of the conserved aromatic residues NPxxY(x)<sub>5,6</sub>F sequence (at boundary helices 7 and 8) generated variants A<sub>1</sub> adenosine receptor that were retained within cell. The mutations disconnected a link between α-helix cytosolic helix 8, likely destabilizing structure proximal carboxyl terminus. mutant receptors rescued by incubation cells with pharmacochaperone, membrane-permeable ligand homosterically binds to receptor; pharmacochaperoning restored density...

10.1124/mol.110.063511 article EN Molecular Pharmacology 2010-03-10
Coming Soon ...